The source and role of RANTES in interstitial lung disease


ABSTRACT: The chemokine "regulated on activation, normal T-cell expressed and secreted" (RANTES) is a potent eosinophil and lymphocyte attractant with particular preference for CD45RO+ T-cells and eosinophils. These cells accumulate in the lungs of patients with sarcoidosis and fibrosing alveolitis. The purpose of this study was to determine whether RANTES mediates the inflammatory cell influx in these diffuse lung diseases.

Cells and number of bronchoalveolar cells expressing RANTES protein were investigated by immunocytochemistry using lavage cells obtained from 22 patients and 11 control subjects. Subsequently, RANTES messenger ribonucleic acid (mRNA) was semiquantitated using reverse transcription polymerase chain reaction (RT-PCR) methodology in unseparated lavage cell pellets in 26 patients and 13 control subjects. Cells expressing RANTES mRNA were identified by in situ hybridization.

RANTES protein expression in lower respiratory tract (LRT) cells was identified in all study groups. The percentage of RANTES+ lavage cells in sarcoidosis was higher than in controls. RANTES was localized in the cytoplasm, mainly in alveolar macrophages (CD68+ cells) in sarcoidosis, and both in alveolar macrophages and eosinophils in fibrosing alveolitis. The same cell types which expressed RANTES protein expressed RANTES mRNA, as assessed by in situ hybridization. Sarcoidosis patients had higher levels of RANTES mRNA than the other groups. RANTES protein was higher in individuals with abnormal lymphocyte numbers: RANTES protein and mRNA expression was significantly correlated with lavage CD45RO+ lymphocyte numbers.

These results indicate that RANTES may mediate T-lymphocyte influx in diffuse lung disease, particularly sarcoidosis. Moreover, they suggest that the cellular source of RANTES is the alveolar macrophage in sarcoidosis, and both macrophages and eosinophils in fibrosing alveolitis.


Interstitial lung disease (ILD) encompasses a large number of disorders characterized by distinct cellular infiltrates in the acinar regions of the lung. The most frequently diagnosed ILDs, sarcoidosis and fibrosing alveolitis, are chronic conditions with distinct pathogenesis, prognosis and composition of inflammatory infiltrates. In sarcoidosis, increased numbers of CD4+ CD45RO+ "memory" T-lymphocytes accumulate within alveolar spaces as a consequence of triggering of the immune response by an, as yet unknown, antigen [1, 2]. The infiltrate in fibrosing alveolitis (FA) is primarily interstitial, but increased numbers of inflammatory cells can also be found in bronchoalveolar lavage (BAL) fluid [3, 4]: eosinophils and lymphocytes are present in the earlier phases of FA, neutrophil infiltration becomes prominent in the later stages of the disease. The majority of the lymphocytes infiltrating the interstitium also express the CD45RO surface marker [5].

The mechanisms responsible for the migration of inflammatory cells from the vasculature to the lung in ILD are not known, but members of the growing family of chemotactic cytokines (chemokines) [6] are prime candidates. In a previous study from our group, we identified interleukin-8 (IL-8) as a possible mediator of neutrophil alveolitis in fibrosing alveolitis associated with systemic sclerosis [7]. Others have suggested that the chemokines, macrophage inflammatory protein-1a (MIP-1α), monocyte chemoattractant protein (MCP-1) and IL-8, contribute to the influx of monocytes and neutrophils to the lung in sarcoidosis and fibrosing alveolitis [8, 9]. However, the role of lymphocyte or eosinophil attractant chemokines in these two interstitial lung diseases has not been investigated.

The chemokine "regulated on activation, normal T-cell expressed and secreted" (RANTES) [10] has been shown in vitro to attract T-lymphocytes, particularly CD45RO+ T-cells [11, 12], and is also an eosinophil attractant and activator [13]. We have, therefore, hypothesized that RANTES may also mediate recruitment of T-lymphocytes and eosinophils to the lower respiratory...
tract in vivo in ILD, and that RANTES expression may be upregulated in patients with lymphocytic and/or eosinophilic alveolitis.

To address this hypothesis, we have investigated RANTES messenger ribonucleic acid (mRNA) and protein expression in lower respiratory tract (LRT) cells of patients with sarcoidosis and patients with FA, and compared it to the expression in control subjects. We have been particularly interested in evaluating which cell types in the LRT express RANTES, and whether there is any relationship between RANTES expression and the number of its target cells (lymphocytes and eosinophils) present on the epithelial lining surface.

Methods

Study population

Subjects for the analysis of cell-associated RANTES protein. In the first stage of the study, expression of RANTES protein was investigated by immunocytochemistry in BAL cells from 33 subjects: patients with fibrosing alveolitis (FA), patients with pulmonary sarcoidosis (S) and control subjects (C). The FA group (n=12; aged 45±3 (SEM) yrs; 3 smokers; 7 receiving treatment) included seven patients with cryptogenic fibrosing alveolitis (CFA) and five patients in whom fibrosing alveolitis was associated with systemic sclerosis (FASSc). The diagnosis of fibrosing alveolitis was based on clinical, radiographic (chest radiography and high resolution computed tomography (HRCT)) and physiological data. FA was confirmed by biopsy in 6 of the 12 individuals. The sarcoidosis group comprised 10 patients (aged 45±3 yrs; 2 smokers; 3 receiving treatment). The diagnosis of sarcoidosis was based on characteristic histological appearances of biopsy samples and/or on a positive Kveim test. The control group (n=11; aged 40±4 yrs; 3 smokers; none receiving treatment) included nine healthy volunteers with no evidence of respiratory disease (N); and two patients with systemic sclerosis without any evidence of FA (SScnoFA), based on clinical, physiological, and radiographic (including HRCT) evidence.

Subjects for mRNA analysis. In the second stage of the study, reverse transcription-polymerase chain reaction (RT-PCR) methodology was utilized to determine RANTES mRNA expression in unseparated BAL cells from 39 subjects: 20 patients with fibrosing alveolitis (7 CFA and 13 FASSc; aged 46±2 yrs; no smokers; 13 receiving treatment); six patients with pulmonary sarcoidosis (aged 47±2 yrs; 2 smokers; 2 receiving treatment); and 13 control subjects (9 N and 4 SScnoFA; aged 47±3 yrs; 1 smoker; none receiving treatment).

In situ hybridization (ISH) experiments for detection of RANTES mRNA in individual BAL cells were performed in three randomly selected patients with CFA and four patients with sarcoidosis.

Approval for studies of human subjects was obtained from the local Ethics Committee.

Bronchoalveolar lavage (BAL)

LRT cells from normal individuals and patients were recovered by BAL, which was performed according to our standard protocol. In brief, during flexible fiberoptic bronchoscopy, 100 mL prewarmed saline was instilled into subsegmental bronchi in three sites: right middle lobe; right lower lobe; and lingula. The cells were separated from the recovered BAL fluid by centrifugation at 200g, 4°C for 7 min. The supernatant obtained after the centrifugation was collected and stored at -20°C until further analysis. The cell pellet was washed twice and resuspended in RPMI-1640 medium, and total cell recovery estimated. Following preparation of cytospin slides, the remaining cells were pelleted, lysed in guanidine isothiocyanate (GITC) lysis buffer with 1% 2-mercaptoethanol (1 mL of buffer per 10^7 cells) and stored at -80°C until ribonucleic acid (RNA) extraction.

BAL differential count and determination of lymphocyte subsets

Cycloheximide preparations were made using Cytospin-2 (Shandon Instr., Sewickly, USA) and utilized for determination of BAL differential count. Cells were fixed with acetone-chloroform, for immunocytochemical analysis of RANTES protein expression and determination of CD45RO+ or CD45RA+ lymphocytes.

Differential cell counts were determined in duplicate from cytospin preparations: 200 May-Grünwald Giemsa stained cells were counted and the percentages and total numbers of each cell type were calculated.

CD45RO+ lymphocytes were identified using an anti-CD45RO monoclonal antibody (Leu45RO; Becton-Dickinson, Heidelberg, Germany). Visualization of positively stained cells was achieved using the alkaline phosphatase/anti-alkaline phosphatase (APAAP) immunocytochemical method [14], employing a rabbit anti-mouse immunoglobulin G (IgG) as a bridging antibody and fast red as a chromogen; the slides were counterstained with haematoxylin. Before immunostaining, non-specific binding sites were blocked using 20% normal rabbit serum (all reagents for APAAP: Dako, Glostrup, Denmark; haematoxylin: BDH, Poole, UK). For all subjects, duplicate slides were processed and 100 lymphocytes were scored on each slide. BAL (total and differential) CD45RO+ lymphocyte counts were derived from the percentage of lymphocytes which were CD45RO+ and BAL lymphocyte total numbers and percentages; (total CD45RO+ lymphocyte count = BAL total lymphocyte count × CD45RO+ percentage/100; differential CD45RO+ count = percentage of laveage cells which were lymphocytes × CD45RO+ percentage/100).

To ensure the reciprocity of CD45RO and CD45RA staining, cytospin preparations from nine randomly selected subjects (five patients and four normals) were used to identify CD45RA+ cells using an anti-CD45RA monoclonal antibody (clone MEM-93; Czech Academy of Science, Prague) followed by APAAP immunostaining.

Determination of cell-associated RANTES protein by immunocytochemistry

To identify cell-associated RANTES protein, cytopsins of bronchoalveolar lavage fluid (BALF) cells were incubated with anti-RANTES monoclonal antibody (R&D
Systems, Abingdon, UK); in parallel slides, the antibody was substituted by an irrelevant negative control monclonal antibody of the same isotype (DAKO, Glostrup, Denmark). As an additional control for the specificity of the staining, the anti-RANTES antibody was pre-incubated with 1 nmol of recombinant human RANTES (R&D Systems). To visualize the specific binding, biotinylated rabbit anti-mouse F(ab')2 antibody was applied to the slides, followed by streptavidin-biotin-complexes conjugated to horseradish peroxidase (DAKO); 3.9 amino-ethyl-carbazole (Sigma, Minneapolis, USA) was used as a chromogen. Endogeneous peroxidase activity was blocked using peroxidase blocking agent (DAKO). At least 200 cells were counted by two independent observers. The results were expressed: 1) as a percentage of positively stained cells of all BAL leucocytes; and 2) as a percentage of positive macrophages, lymphocytes and eosinophils of the total number of the respective cell type. The identity of the RANTES+ cells was confirmed by parallel staining of cytopsins with anti-CD68 (DAKO; macrophase marker), anti-CD2 (lymphocyte marker), and visualized as for RANTES. Quantitative morphometry of RANTES+ cells was compared with that of CD68+ and CD2+ cells.

**RNA extraction and reverse transcription**

Total cellular RNA was isolated using the single step acid-GITC method [15]. The RNA pellet was dissolved in 50 µL of sterile deionized water, 40 U of human placental ribonuclease (RNAse) inhibitor (Promega, Southampton, UK) was added, and the samples were stored at -80°C until further use.

The complementary deoxyribonucleic acid (cDNA) for PCR amplification was obtained by reverse transcription of mRNA using oligo(dT) primer [16]. Each reaction contained 1 µg RNA, 0.4 µg oligo(dT)15 primer, 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton-X 100, 5 mM MgCl2, 1 mM each deoxynucleotide triphosphate (dNTP), 20 U Avian myeloblastosis virus (AMV) reverse transcriptase HC (Promega), and 20–40 U placental RNAse inhibitor, in a total reaction volume of 30 µL. After initial denaturation (5 min at 95°C), a range (20–36) of amplification cycles was performed using a PHC3 thermocycler (Techne, Cambridge, UK). One cycle consisted of denaturation at 95°C for 45 s, annealing at 55°C for 45 s and extension at 72°C for 90 s. After the last cycle, final extension (10 min at 72°C) was carried out and the reaction was terminated by chilling to 4°C. A negative control reaction containing all components except template cDNA was set up with every PCR experiment.

To define the optimum PCR conditions, a number of preliminary studies were performed: firstly, kinetic studies of RANTES and β-actin cDNA amplification determined the optimal number of amplification cycles for each gene, so that the product was within the exponential phase of the amplification process [19]; secondly, two randomly selected cDNA samples (one control and one patient sample) were amplified on four different days and showed no significant difference in variance between assays of the two samples; and thirdly, intra-assay variability was assessed in triplicate amplification of two cDNA samples (one control and one patient) on the same day, and no significant difference in variance was observed (data not shown).

**Polymerase chain reaction**

PCR reactions were performed with specific oligonucleotide primers designed from the published cDNA sequences of RANTES [10] and β-actin [18]. RANTES: 5'TCATTGTGCTAATCCTCTGCA' (sense, bases 61–80); 5'CCTAGCTCATCTCTCCAAAGAG' (antisense, bases 284–303); β-actin: 5'TCTTTGTCATCCACGAAACT' (sense, bases 852–872); 5'GAAGCTTTCGCGGTGACGAGAT' (antisense, bases 1146–1166). The predicted sizes of the amplified RANTES and β-actin cDNA products were 243 and 315 base pairs (bp), respectively.

The PCR reaction mix contained the forward and reverse primers (0.25 mM each), dNTPs (0.2 mM each), 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 0.1 mg·mL gelatine, 1.5 U Taq polymerase (Boehringer Mannheim, Lewes, UK) and 10 µL cDNA, in a total reaction volume of 50 µL. After initial denaturation (5 min at 95°C), a range (20–36) of amplification cycles was performed using a PHC3 thermocycler (Techne, Cambridge, UK). One cycle consisted of denaturation at 95°C for 45 s, annealing at 55°C for 45 s and extension at 72°C for 90 s. After the last cycle, final extension (10 min at 72°C) was carried out and the reaction was terminated by chilling to 4°C. A negative control reaction containing all components except template cDNA was set up with every PCR experiment.

To define the optimum PCR conditions, a number of preliminary studies were performed: firstly, kinetic studies of RANTES and β-actin cDNA amplification determined the optimal number of amplification cycles for each gene, so that the product was within the exponential phase of the amplification process [19]; secondly, two randomly selected cDNA samples (one control and one patient sample) were amplified on four different days and showed no significant difference in variance between assays of the two samples; and thirdly, intra-assay variability was assessed in triplicate amplification of two cDNA samples (one control and one patient) on the same day, and no significant difference in variance was observed (data not shown).

**Identification of PCR products, measurements and quantification of RANTES mRNA expression**

The amplification products were visualized by ethidium bromide fluorescence after 3% agarose gel electrophoresis.

To verify that the bands obtained represented the specific RANTES and β-actin amplification products, the size of the bands was determined using a low molecular weight marker (pBR 322 DNA/Hae III; Boehringer Mannheim). The sizes were then compared with those predicted from the locations of the primers within RANTES or β-actin cDNA sequences.

For measurements of PCR products, the negative images of the gels on Polaroid type 665 film were scanned on a laser densitometer, and the optical density (OD) values for the individual products were obtained. RANTES mRNA expression was quantified by normalizing RANTES expression to β-actin, a gene expressed constitutively with little variability; similar quantitative PCR has previously been applied to control for variability in the amount of input RNA in studies of chemokine mRNA expression [7, 20]. The RANTES/β-actin optical density ratios (ODR) were derived for each subject by comparison of optical densities of RANTES with the optical density of β-actin amplification products (ODR = OD RANTES/OD β-actin).

In situ hybridization for RANTES mRNA (ISH)

ISH was performed on cytopsins of BALF cells fixed with 4% paraformaldehyde, using an oligonucleotide
probe cocktail to human RANTES (R&D Systems, Abingdon, UK); the cocktail consisted of three digoxigenin-labelled probes specific to different regions of the RANTES gene. Prior to application of the probe, negative control slides were pretreated with RNase A, to confirm the specificity of the probe for RNA and to exclude any artefacts which might arise from nonspecific binding during the detection procedure. The hybridization of the probe to RNA was visualized using anti-digoxigenin F(ab’)2 polyclonal antibody conjugated to alkaline phosphatase (Boehringer Mannheim, Lewes, UK); the binding was visualized by a nitroblue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl phosphate (BCIP) substrate system and the slides were counterstained with nuclear red. The slides were evaluated for characterization of the cellular types expressing RANTES mRNA by two independent observers.

Statistical analysis

Mann-Whitney U-test was employed to test for differences in RANTES mRNA or protein expression between the control and the disease groups. Spearman’s rank correlation was used to assess the association between RANTES mRNA or protein data, and BAL cell counts and lymphocyte subsets. A p-value less than 0.05 was considered statistically significant.

Results

RANTES protein expression in bronchoalveolar lavage cells

RANTES protein was found to be expressed in BAL cells from all but one of the 33 subjects. The percentage of RANTES+ BAL cells in sarcoidosis (median 24%, range 1–41%) was higher than that in controls (median 7%, range 0–28%) (p<0.05) (fig. 1). The percentage of RANTES+ BAL cells in FA (median 12%, range 1–28%) did not differ from controls.

The contribution of the individual cell types to overall RANTES protein expression was distinct in FA and sarcoidosis (fig. 2). In sarcoidosis, alveolar macrophages, defined by morphological criteria and the expression of the CD68 surface marker, appeared to be the major source of RANTES protein: 92% of RANTES+ BAL cells were macrophages. The contribution of alveolar macrophages to overall RANTES expression in FA was substantially lower, and, interestingly, a significant proportion (32%) of RANTES+ cells were eosinophils. The contribution of T-lymphocytes (CD2+ cells) to RANTES immunopositivity in all three groups was substantially lower (median 0.2%, range 0–6% of overall expression). Representative examples of RANTES protein expression in the BAL cells are shown in figures 3 and 4. The

Fig. 1. – RANTES protein expression in BAL cells of patients with fibrosing alveolitis (n=12), sarcoidosis (n=10), and controls (n=11). Cell-associated RANTES protein was determined by immunocytochemistry in cytocentrifuge preparations of BAL cells. The percentage of RANTES+ BAL cells in sarcoidosis (median 24%, range 1–41%) was higher than that in controls (median 7%, range 0–28%) (p<0.05) (fig. 1). The percentage of RANTES+ BAL cells in FA (median 12%, range 1–28%) did not differ from controls.

Fig. 2. – RANTES protein expression in individual cells types. The data show the contribution of individual cells types to the total percentage of RANTES positivity: a) in patients with sarcoidosis; b) in patients with fibrosing alveolitis; and c) controls. Median values are presented. Tot: total BAL cells; Mac: macrophages; Lym: lymphocytes; Neu: neutrophils; Eos: eosinophils. For further definitions see legend to figure 1.
The latter figure compares the patterns of RANTES, CD68 and CD2 immunoreactivity in the lavage cells of a patient with sarcoidosis, and demonstrates that the RANTES+ cells are not lymphocytes. Further support for this comes from morphometry. The diameters of the CD68+ cells (macrophages) ranged 12.2–30.5 µm (mean±sd, 20.9±3.8 µm), and the majority of the RANTES+ cells were in this size range. By contrast, the range of sizes of CD2+ cells (lymphocytes) was 6.2–9.1 µm (7.7±0.6 µm), and only 8% of RANTES+ cells were of this size (data not shown).

The expression of RANTES protein was localized in the cytoplasm, rather than membrane-associated, because permeabilization of cell membranes was necessary prior to immunocytochemistry to obtain staining. The appearance of RANTES expression in eosinophils

Fig. 3. – Detection of RANTES protein in BAL cells. Positively stained cells (red colour) were observed in BAL cytospin preparations incubated with anti-RANTES antibody (A and B), but not with the irrelevant control antibody (C). RANTES protein was localized to the cytoplasm of macrophages (A) and eosinophils (B). For definitions see legend to figure 1. (Avidin-biotin enzyme complex method with 3-amino-9-ethyl carbazole as substrate and counterstained with haematoxylin; internal scale bar = 10 µm).

Fig. 4. – Identification of RANTES-positive cells. Cell types expressing RANTES were defined by staining patterns with anti-CD68 (macrophages) and anti-CD2 (lymphocytes). Examples of the staining patterns are shown. A) RANTES; B) CD68; C) CD2; D) negative isotype-matched control. Note that RANTES+ cells are of the morphology of CD68+ cells seen in B, and not that of the CD2+ cells, seen in C. RANTES: regulated on activation, normal T-cell expressed and secreted. (internal scale bar = 10 µm).
was predominantly granular, suggesting that RANTES is eosinophil granule-associated.

**RANTES mRNA expression in the lower respiratory tract cells**

**RT-PCR analysis.** RANTES mRNA was detected in unseparated BAL cells from all 39 patients and control subjects. Semiquantitative analysis of RANTES mRNA expression, utilizing RANTES/β-actin ratio (ODR), showed that RANTES transcripts were upregulated in patients with sarcoidosis (fig. 5). All sarcoidosis patients had an ODR higher than 0.2, by comparison with 11 of 20 patients with FA and 4 of 13 controls. The difference in RANTES mRNA expression between sarcoidosis patients and the control group, and also between sarcoidosis patients and the FA group was significant (p=0.02 and p=0.04, respectively). In the FA group, more individuals expressed higher levels of RANTES mRNA than in the control group: 55% of FA subjects had ODR higher than 0.2 compared with 31% controls, but the difference between the groups was not significant.

**RANTES mRNA expression assessed by in situ hybridization**

To confirm that the RANTES protein, which is localized to the cytoplasm of the BAL cells, is synthesized by these cells and not taken up from the local milieu, ISH with RANTES specific oligonucleotide probes was performed on BAL cell cytospins. In lavage samples obtained from the sarcoidosis and FA patients, RANTES mRNA expression was found almost exclusively in alveolar macrophages and eosinophils (fig. 6). Lymphocytes rarely expressed RANTES mRNA: in all samples less than 5% of lymphocytes contained RANTES mRNA.

**RANTES expression and BAL inflammatory cells**

**Lymphocytes and eosinophils in the lower respiratory tract.** There was a significant difference (p=0.003) between the percentages of BAL lymphocytes obtained from the group of sarcoidosis patients and from the control group (median values 24%, range 10–28%; and 4%, 2–21%, respectively). The FA group and controls did not differ significantly in percentages of BAL lymphocytes (median 8%, range 1–61%; and 4%, 2–21%, respectively). Regardless of the proportion of lymphocytes in the lavage return, the great majority (median 73%, range 62–89%) of BAL lymphocytes in all patients and control subjects expressed CD45RO. The percentage of BAL cells which were CD45RO+ (differential CD45RO+ lymphocyte count) ranged 0.6–54%, and total CD45RO+ lymphocyte numbers ranged 0.1×10⁶ to 27.2×10⁶. By contrast, CD45RA immunostaining revealed that only a minor proportion of BAL lymphocytes (median 6%, range 0–15%) expressed CD45RA, consistent with the reciprocal expression of CD45RO and CD45RA on T-lymphocytes.

BAL eosinophil numbers were higher in FA (median 7%, range 1.8–15.5%) than in the other two groups (controls 0.5 (0–5.0)% and sarcoidosis 0.7 (0–3.3)%, p=0.001).
Relationship between RANTES expression and the number of lymphocytes and eosinophils lavaged from the lower respiratory tract

Because RANTES is a lymphocyte and eosinophil attractant, the possible relationship between RANTES expression and the number of its potential target cells lavaged from the LRT was investigated.

There was a clear association between the number of BAL lymphocytes and RANTES mRNA and protein expression (fig. 7). In subjects with an increased number of lymphocytes in BAL (>13%), RANTES mRNA and protein expression was significantly higher than in the subjects with normal BAL lymphocyte numbers (<13%) (p=0.02 (mRNA); and p=0.04 (protein)).

This was further explored by correlating RANTES/β-actin ratio (ODR) with the percentage and total number of lymphocytes, macrophages, neutrophils and eosinophils obtained by BAL. Of these variables, BAL differential lymphocyte count showed a positive correlation (rs=0.63; p=0.0001) with the ODR (fig. 8a). The same relationship was observed when comparisons were made between ODR and total BAL cell numbers. The numbers of lavaged eosinophils and neutrophils did not correlate with RANTES mRNA expression (p>0.1).

Importantly, RANTES mRNA expression was low (median 0.083, range 0.006–0.179) in the control subjects.
with <4% lymphocytes in lavage, by comparison with 0.316 (0.059–0.492) when lymphocyte percentages were >5%, providing further support for the concept of RANTES regulation of T-cell traffic in the normal state.

RANTES is a T-lymphocyte attractant with preference for CD45RO+ "memory" T-cells. Therefore, in a subgroup of the patients and controls, the association between RANTES mRNA expression and BAL lymphocyte subsets was analysed. There was significant correlation (r=0.57; p=0.001) between ODR and BAL CD45RO+ differential (fig. 8b) and total lymphocyte counts.

The relationship between RANTES protein expression and numbers of BAL inflammatory cells was also investigated. The percentage of RANTES positive BAL total cells showed a weak positive correlation (r=0.39; p=0.03), with the number of BAL lymphocytes (fig. 8c), but did not correlate with neutrophils and eosinophils.

Discussion

This study has demonstrated that RANTES is expressed at the protein and mRNA level in the lower respiratory tracts of patients with interstitial lung diseases, that it is associated with the accumulation of "memory" T-cells within the lung and, importantly, that the major sites of RANTES synthesis are macrophages alone in sarcoidosis, but macrophages and eosinophils in fibrosing alveolitis. Although the data are obtained from cells recovered by BAL alone, the study suggests that RANTES is a likely potent recruiter of T-lymphocytes to the lower respiratory tract in vivo, and thus contributes to the progression of the inflammatory infiltrate in interstitial lung disease.

The investigations of RANTES mRNA and protein expression in LRT cells obtained by BAL revealed that RANTES expression was upregulated by comparison with controls in sarcoidosis, a disease characterized by a lymphocytic alveolitis, but not in FA. However, the relationship of RANTES with lymphocyte accumulation independent of disease is shown by the significant increase of RANTES expression in individuals whose lymphocyte numbers exceeded the normal range.

The semiquantification of mRNA is subject to some variability, and we have attempted to ensure the reproducibility and specificity by careful definition of experimental conditions. In this regard, a series of preliminary experiments were performed to define the optimum conditions for each primer pair, and to confirm the reproducibility of the product amount by replicate experiments on the same day and repeat amplification of the same cDNA on separate days. Furthermore, by normalization of RANTES expression data to the transcription products of the constitutively expressed β-actin gene the positivity of overinterpreting the RT-PCR results was avoided. The use of this variant of RT-PCR was substantiated by other studies [7, 21], which showed significant differences between expression of the chemokine IL-8 in cells from normal and fibrotic lung using this normalization method.

RANTES in the bronchoalveolar compartment

Knowledge of RANTES expression in vivo in human inflammatory lung disease has so far been limited to asthma and, apart from the study of Wang et al. [22], which described the presence of RANTES protein in bronchial epithelial cells, there have been no reports on RANTES expression in the bronchoalveolar compartment. In the present study, RANTES mRNA and protein were localized intracellularly mainly in alveolar macrophages, identified by morphology and CD68 positivity, and eosinophils. The predominant RANTES+ cell was the macrophage in sarcoidosis, whilst in FA there was a high number of eosinophils, which expressed RANTES mRNA and protein. These findings extend current knowledge concerning the spectrum of cells which express RANTES in the human lung, especially in the context of interstitial lung disease. Moreover, the demonstration that different cell types express RANTES in FA and in sarcoidosis supports the presumption of Ying et al. [23], that cell types expressing RANTES may differ in various types of inflammation.

Human alveolar macrophages have been shown in vivo to express other chemokines, e.g. MIP-1α [8]; however, there have been no reports about their in vivo expression of RANTES. Our finding of intracellular expression of RANTES in BAL macrophages can be linked to the recent findings that these cells may release RANTES when cultivated in vitro [24, 25].

RANTES mRNA and protein have previously been detected in eosinophils isolated from peripheral blood of normal and atopic donors [26, 27], but this was not explored in lung eosinophils. In support of our findings in lung cells, Lim et al. [26] have shown that immunoreactive RANTES was localized intracellularly in eosinophils, in a granule-associated staining pattern. Moreover, we detected RANTES mRNA in eosinophils by ISH, consistent with the concept that BAL eosinophils can synthesize and store RANTES protein. Although the significance of this phenomenon is not clear, it may reflect the capability of eosinophils to play a central role in the evolution of the inflammatory component of FA, consistent with our previous studies, which showed that eosinophils are recruited to the lung at an early stage of disease defined by CT extent [28].

The relationship of RANTES expression and interstitial lung disease

The present studies of RANTES protein and mRNA expression in unseparated BAL cell pellets using RT-PCR methodology showed a correlation between RANTES mRNA, expression and the number of BAL lymphocytes. This observation is in keeping with the known in vitro lymphoattractant properties of RANTES [11, 12], and is, indeed, in agreement with our initial hypothesis that RANTES attracts lymphocytes to the LRT in vivo.

The increase of RANTES expression in alveolar macrophages of patients with sarcoidosis may be relevant to the development of the T-lymphocytic alveolitis in this disease. This hypothesis is supported by reports of the localization of RANTES mRNA to macrophages within the granulomas related to sarcoidosis or tuberculosis [25]. In this context, it is interesting that Mycobacterium tuberculosis, which is considered to be a possible antigenic trigger in sarcoidosis, can induce RANTES production [29]. By contrast with sarcoidosis, patients with FA did not show a significant difference from controls.
with regard to the total number of cells expressing RANTES protein or the levels of RANTES mRNA in BAL cell pellets. However, in FA the T-cell accumulation is predominantly interstitial and fewer T-cells are present on the epithelial surface. Where they were present in high numbers, it was found that RANTES was upregulated, but this was not a disease-dependent observation, being found in control samples also. A second explanation for the difference between FA and sarcoidosis may be that sarcoidosis is the product of a type 1 T-helper (Th1) T-cell response, whereas FA involves a predominantly type 2 T-helper (Th2) type of immune response. The Th1 cytokine, interferon-γ (IFN γ), which is produced by lavage [30] and interstitial [31] cells in sarcoidosis, upregulates RANTES, while the Th2 cell product, interleukin-4 (IL-4), inhibits RANTES [32]. We [33] and others [31] have previously shown that the cytokine expression in FA is predominantly of Th2 pattern.

Nonetheless, our data suggest that RANTES has a role in T-cell accumulation in both the diseases studied, and is upregulated most in sarcoidosis, which is a classical T-cell mediated disorder. The fact that RANTES was found to be expressed in the normal lung may implicate this cytokine in the recruitment of lymphocytes to the lung as a part of normal host defence (immune surveillance).

In conclusion, we have demonstrated that the chemokine RANTES is implicated in the attraction of T-lymphocytes to the lower respiratory tract, and that the upregulation of RANTES messenger ribonucleic acid and protein expression is relevant to the development of the lymphocytic alveolitis in sarcoidosis, and possibly to further propagation of the inflammatory infiltrate in fibrosing alveolitis. Further studies of the contribution of RANTES to the pathogenesis of interstitial lung disease should involve determination of functional activity of RANTES protein in bronchocoevalveal lavage fluid, and should address the question of differential expression of RANTES at different stages of disease.

Acknowledgements: The authors thank P. Balharova for technical assistance and V. Lichnovsky for help with photomicrography.

References


